Please enable JS

Investors & Media

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
Jun-19-2018CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
Patent granted for groundbreaking work by Jennifer Doudna's and Emmanuelle Charpentier's research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuel... 
Printer Friendly Version
Jun-05-2018CRISPR Therapeutics to Participate in Three June Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in June 2018. The 2018 BIO International Convention Panel: Advances in Genome Editing – The Next Frontier in Human Health Date: Wednesday, June 6, 2018 Presentation: 1:45 –... 
Printer Friendly Version
May-30-2018CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment of sickle cell disease pending the resolution of certain questions that will be provided by the FDA as part of its review of the IND.  The IND was submitted... 
Printer Friendly Version
May-15-2018CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will make a series of presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 16-19, 2018 at the Hilton Chicago. Title: Gene Editing Workshop Presenter: Tirtha Chakraborty, Ph.D., Head o... 
Printer Friendly Version
May-08-2018CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
-On track to begin CTX001 clinical study in hemoglobinopathies in 2018- -On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies- -$341.8 million in cash as of March 31, 2018- ZUG, Switzerland and CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today provided a business update and announced financi... 
Printer Friendly Version
May-03-2018CRISPR Therapeutics to Participate in May Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at two upcoming Investor Conferences. Deutsche Bank's 43rd Annual Health Care Conference Date: Wednesday, May 9, 2018 Presentation: 10:40-11:15 AM ET Location: Intercontinental Hotel, Boston, ... 
Printer Friendly Version
Apr-16-2018CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent cell killing- ZUG, Switzerland and CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the presentation of new data from the company’s all... 
Printer Friendly Version
Apr-13-2018CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL. Presentation: Allogeneic chimeric antigen receptor T cel... 
Printer Friendly Version
Apr-04-2018CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Steve Caffé, M.D., as Head of Regulatory Affairs. Dr. Caffé brings to CRISPR a 25-year track record in global product development and regulatory affairs, having held senior leadership positions at many leading biotechnology and pharmaceuticals companies. ... 
Printer Friendly Version
Mar-26-2018CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the retirement of Dr. Tyler Dylan-Hyde as Chief Legal Officer and the appointment of Shelby Walker as Head of Intellectual Property. “Tyler joined CRISPR in its early stages and made significant contributions to the Company’s success during his tenure,” commente... 
Printer Friendly Version
Mar-08-2018CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy - - Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December ... 
Printer Friendly Version
Feb-21-2018CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.  2018 RBC Capital Markets Global Healthcare Conference Date: Thursday, February 22, 2018 Presentation: 8:00-8:25 AM ET Webcast available under Investor Relations tab a... 
Printer Friendly Version
Feb-08-2018CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that Bill Lundberg, MD, is stepping down as Chief Scientific Officer of CRISPR. Going forward, Dr. Lundberg will serve as a Senior Advisor to the Company and has been named Head of CRISPR’s Scientific Advisory Board. “I have had the privilege of working with a wo... 
Printer Friendly Version
Jan-04-2018CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 5,000,000 of its common shares at a public offering price of $22.75 per share, before underwriting discounts. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to an additio... 
Printer Friendly Version
Jan-03-2018CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $100,000,000 of its common shares. In addition, CRISPR Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of its common shares in connection with the pub... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet